Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

MGC Pharmaceuticals Ltd appoints new COO and UK advisor 

Published 04/10/2022, 07:36
Updated 04/10/2022, 08:11
© Reuters.  MGC Pharmaceuticals Ltd appoints new COO and UK advisor 

© Reuters. MGC Pharmaceuticals Ltd appoints new COO and UK advisor 

MGC Pharmaceuticals Ltd said it has appointed Yifat Steuer as its new chief operating officer and deputy chief executive officer.

Steuer, a qualified chartered accountant, has over 20 years of experience as an executive, working across a range of pharmaceutical companies including Johnson & Johnson (NYSE:JNJ) and GlaxoSmithKline, as well as with SMEs and start-ups, the bio-pharma company said in a statement.

She will work closely with company CEO Roby Zomer to execute on MGC Pharma's business strategy, utilising her experience in in pharmaceuticals, manufacturing, logistics, medical technology and digital health.

Additionally, MGC Pharma announced the formal appointment of UK capital markets advisor Hannam & Partners as financial and corporate advisors to the company with immediate effect

Hannam & Partners is "a highly regarded UK advisory firm with a long track record in UK capital markets" and more recently in the UK and EU cannabis sector, it noted.

MGC Pharma also said the role of chairman Brett Mitchell has changed from an executive to a non-executive position, in line with the corporate structure of UK listed companies.

The company said it is holding an investor update on 11 October following the publication of its 2022 annual report.

Read more on Proactive Investors UK

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.